Figure 2
The number of circulatory Th17 cells is decreased in HER2+ breast cancer patients. The frequency of Th17 cells in HER2− breast cancer patients (grey) did not differ from that measured in healthy individuals (black). HER2+ breast cancer patients (white) had significantly lower Th17 frequency compared with both healthy individuals and HER2− patients, and the frequency of Th17s increased during trastuzumab therapy. Th17 frequency was measured as the frequency of CD4+IL17A+ T cells as a percentage of total CD4+ cells. Error bars represent±s.e. P-values < 0.05, as measured by the Mann–Whitney U-test, were considered significant.
